(February 1, 2017, 1:02 PM EST) -- WILMINGTON, Del. — In a consolidated patent dispute over plans by myriad defendants to market and sell generic Copaxone, a Delaware federal judge on Jan. 30 deemed the four patents that cover the brand-name drug invalid under the Patent Act, 35 U.S.C. § 103(a) (In re: Copaxone Consolidated Cases, No. 14-1171, D. Del., 2017 U.S. Dist. LEXIS 12168)....